<DOC>
	<DOCNO>NCT01300455</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , effect multiple dos suvorexant ( MK-4305 ) respiratory function participant mild moderate obstructive sleep apnea ( OSA ) compare administration placebo . The primary hypothesis study multiple dos MK-4305 produce clinically significant increase Apnea-Hypopnea Index ( AHI ) participant mild moderate OSA , compare placebo .</brief_summary>
	<brief_title>Effects Suvorexant Participants With Obstructive Sleep Apnea ( MK-4305-036 )</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Female participant reproductive potential must demonstrate serum βhuman chorionic gonadotrophin ( hCG ) level consistent nongravid state prestudy ( screen ) visit agree use ( and/or partner use ) two ( 2 ) acceptable method birth control begin prestudy visit throughout study . Women postmenopausal without menses least 1 year follicle stimulate hormone ( FSH ) value postmenopausal range upon prestudy ( screen ) evaluation , and/or status post hysterectomy , oophorectomy tubal ligation may participate . Participants Body Mass Index ( BMI ) ≤40 kg/m2 prestudy ( screen ) visit . Participants good health base medical history , physical examination , vital sign measurement , laboratory safety test . Participants without clinically significant abnormality electrocardiogram ( ECG ) perform prestudy ( screen ) visit and/or prior administration initial dose study drug . Participants International Classification Sleep Disorders diagnosis OSA . Participants confirm mild moderate OSA ( define mild OSA AHI ≥5 &lt; 15 , moderate OSA AHI ≥15 &lt; 30 ) base screen nighttime polysomnography ( NPSG ) . Participants usual bedtime 20:00 ( 8:00 post meridiem [ PM ] ) 00:30 ( 12:30 ante meridiem [ AM ) ] subject unusual change sleep routine sleep 4 hour per night . Participants must complete sleep history diary least 5 consecutive day 21 day prior screen PSG visit . Participant nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month ; participant discontinue smoke use nicotine/nicotine contain product least approximately 3 month may enrol study discretion investigator . Participants use continuous positive airway pressure devise ( CPAP ) dental appliance within precede 7 day prior screen NPSG Visit , require use CPAP dental appliance course study ( 7 day prior screen NPSG , throughout study [ include washout interval treatment period ] , poststudy visit ) . Participants OSA evidence another clinically significant , active pulmonary disorder bronchiectasis , emphysema , asthma documented history , physical examination , chest x‑ray . Participant either history within past 6 month prior prestudy visit current evidence unstable clinically significant cardiovascular disorder , include limited acute coronary syndrome , unstable angina , congestive heart failure , cardiogenic syncope , cardiomyopathy , symptomatic arrhythmia , orthostatic hypotension , uncontrolled hypertension . Participants abnormal prerandomization laboratory value clinically significant , unexplained laboratory abnormality opinion investigator alanine transaminase ( ALT ) &gt; 1.5 x upper limit normal ( x ULN ) , aspartate transaminase ( AST ) &gt; 1.5 x ULN , total bilirubin &gt; 1.5 x ULN , serum creatinine &gt; 2 mg/dL . Participants history diagnosis narcolepsy , cataplexy ( familial idiopathic ) , circadian rhythm sleep disorder , parasomnia include nightmare disorder , sleep terror disorder , sleepwalk disorder , REM behavior disorder , periodic limb movement ( PLM ) disorder , restless legs syndrome , primary hypersomnia . Participants screen PSG record oxygen ( O2 ) saturation &lt; 80 % ≥5 % total sleep time , &gt; 10 PLM per hour associate arousal ( periodic limb movement arousal index [ PLMAI ] ) . Participant mentally legally incapacitate , significant emotional problem time prestudy ( screen ) visit expect conduct study history clinically significant psychiatric disorder last 5 10 year . Participant situational depression may enrol study discretion investigator . Participant lifetime history bipolar disorder , psychotic disorder , posttraumatic stress disorder ; , psychiatric condition require treatment prohibit medication ; , psychiatric condition , investigator 's opinion , would interfere participant 's ability participate study . Participant , opinion investigator , history current evidence condition , therapy , lab ECG abnormality circumstance might confound result study , interfere participant 's participation full duration study . Participant history neurological disorder , include limited seizure disorder ( single episode childhood febrile seizure ) , stroke , transient ischemic attack , multiple sclerosis , cognitive impairment , significant head trauma sustain loss consciousness within last 10 year . Participant history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease . Participants history uncomplicated kidney stone may enrol study discretion investigator . Participant history neoplastic disease except : 1. adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix may participate study ; 2. participant malignancy successfully treat ≥10 year prior prestudy ( screen ) visit , judgment Investigator treat physician , appropriate followup reveal evidence recurrence time treatment time prestudy ( screen ) visit , 3. participant , , opinion Investigator , highly unlikely sustain recurrence duration study . Participant nursing mother . Participant positive screening urine alcohol test drug test . Participant need 3 toilet visit night . Participant take , plan take , one prohibit concomitant medication . Participant consume excessive amount alcohol ( great 3 glass alcoholic beverage ) , excessive amount coffee , tea , cola , caffeinated beverage per day . Participant major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy ( screen ) visit . Participant history significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food . Participant currently regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 2 year . Participant work night shift able avoid night shift work within 2 week treatment visit ( study start study ) . Participant travel across 3 time zone ( transmeridian travel ) last 1 week prior study start . Participant imminent risk selfharm harm others Any concern investigator regard safe participation participant study reason ; investigator considers participant inappropriate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>obstructive sleep apnea</keyword>
	<keyword>orexin receptor antagonist</keyword>
</DOC>